| Net Profit Qtr YoY | 349.36%Growth |
|---|---|
| Market Cap | ₹66,719.68 CrLarge Cap |
| Revenue TTM | ₹17,321.1 CrOperating |
| RSI | 39.36Neutral Zone |
Key highlights
- Approval granted by Japan's Ministry of Health, Labour and Welfare (MHLW)
- Product is a biosimilar version of Neulasta used in oncology supportive care
- Developed and manufactured by Biocon Biologics Ltd for global markets
- Sandoz K.K. secured exclusive rights for promotion and distribution in Japan
- Global Regulatory Partners Japan to serve as the Marketing Authorization Holder
What Approval Was Received?
Biocon Biologics Ltd has secured marketing authorization from the Japanese Ministry of Health, Labour and Welfare (MHLW) for its pegfilgrastim biosimilar. This product is a biosimilar to Neulasta, a medication used to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients treated with chemotherapy. The development and manufacturing are handled by Biocon Biologics Ltd, utilizing its established global manufacturing infrastructure to serve the Japanese healthcare market.
This regulatory milestone represents a key expansion of the company's oncology presence in a major international pharmaceutical territory.
Why This Approval Matters
- Strengthens Biocon’s existing portfolio of biosimilar products within the Japanese regulatory framework
- Leverages an exclusive partnership with Sandoz K.K. for local promotion, sales, and distribution
- Enhances the company's commitment to providing high-quality, affordable biologics on a global scale
- Utilizes Global Regulatory Partners Japan to serve as the local Marketing Authorization Holder
- Positions the company to capture market share in the biosimilar segment for supportive cancer care
Path to Market
The commercialization of the pegfilgrastim biosimilar in Japan follows a collaborative model involving multiple stakeholders. While Biocon Biologics Ltd remains the parent entity responsible for the product's development and manufacturing, Global Regulatory Partners Japan acts as the bridge for regulatory compliance. The final reach to patients and healthcare providers is facilitated by Sandoz K.K., which holds exclusive distribution rights.
This structured approach allows Biocon to bypass the overhead of a direct sales force while maintaining its role as the primary manufacturer.
Financial Context
Financially, Biocon Limited reported a Trailing Twelve Month operating revenue of ₹17,321.1 crore, with a significant quarterly net profit growth of 349.36 percent year on year in the most recent results. Despite a decline in annual net profit for the previous fiscal year, the company maintains a Durability Score of 60, indicating relative financial health. The expansion into Japan’s biosimilar market is aligned with the company’s broader strategy to monetize its research and development investments and improve its price to earnings valuation, which currently stands at 134.71.
“This approval further strengthens Biocon’s portfolio of biosimilar products in Japan and reaffirms the company’s commitment to increasing patient access to high-quality and affordable medications globally.”
| Share price | ₹409.4 |
|---|---|
| Market capitalisation | ₹66,719.68 Cr |
| Revenue (annual) | ₹16,927.00 Cr |
| Net profit (annual) | ₹385.60 Cr |
| Revenue (latest quarter) | ₹4,336.00 Cr-4.00% vs previous quarter |
| Net profit (latest quarter) | ₹141.10 Cr+12.07% vs previous quarter |
| P/E (TTM) | 134.71×Sector 46.94× |
| Promoter holding | 44.68%-0.23% QoQ |
| FII holding | 8.14%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Biocon Limited announcing the marketing approval for Pegfilgrastim biosimilar in Japan. Market figures from a third-party data provider.
